Sector | Healthcare |
Industry | - |
Day Range | 2.41 | 2.47 |
52-Wk Range | - | - |
Last Close | 2.35 |
Mkt Cap (m) | 398.97 |
Dividend yield | - |
ISIN | US92337C1045 |
Volume | 110.00 |
Exchange Venue | NAS |
Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.
Price/Earning | - |
Price/Book | 3.07 |
Price/Sales | 3.33 |
P/CF | - |
Rev Growth (3 year avg) | - |
EPS Growth (3 year avg) | - |
Operating Margin % | - |
Net Margin % | - |
Return on Equity | - |
Debt/Equity | - |
en 27/04/2020 |
en 31/12/2019 |
Please refer to the below issuer website for further documents.
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Revenue (m) | 0.00 | 0.00 | 0.00 | 26.72 | 17.46 | - |
Operating Income (m) | -58.20 | -37.00 | -67.80 | -94.78 | -132.34 | - |
Net Income (m) | -57.87 | -36.44 | -67.80 | -72.43 | -149.21 | - |
Basic EPS | -1.61 | -0.99 | -1.76 | -1.12 | -2.00 | - |
Avg. Diluted Shares Outstanding (m) | 35.93 | 36.99 | 38.42 | 69.32 | 74.58 | - |
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Current Assets (m) | 110.84 | 81.30 | 87.79 | 253.26 | 84.96 | - |
Non Current Assets (m) | 2.25 | 2.33 | 2.00 | 23.98 | 60.09 | - |
Total Assets (m) | 113.09 | 83.63 | 89.79 | 277.24 | 145.05 | - |
Current Liabilities (m) | 10.11 | 10.99 | 17.13 | 37.08 | 29.89 | - |
Total Liabilities (m) | - | - | - | - | - | - |
Total Equity (m) | 102.47 | 72.30 | 57.68 | 124.30 | 7.17 | - |
USD | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
Operating Cash Flows (m) | -45.56 | -29.48 | -57.31 | -74.52 | -138.52 | - |
Capital Expenditure (m) | -0.21 | -0.04 | - | -23.51 | -0.01 | - |